Table 3.

Eligibility criteria

Inclusion criteria	Exclusion criteria
Addresses ethical aspects of MDA use or implementation for NTD control or elimination in at-risk communities	Does not address MDA strategies Addresses MDA for the control or elimination of other diseases (not NTDs) Does not address ethical aspects Ethical aspects mentioned are not directly related to MDA
MDA is examined as a possible PH intervention for NTD control or elimination	Publication solely compares different MDA regimens (e.g., drug types, dosages, target groups)
All PC-NTDs listed in WHO roadmap (2021–2030)	Diseases not targeted by WHO roadmap for NTDs (e.g., malaria)
Written in English, German or French languages	Written in languages other than English, German, French
All types of publications in scientific journals, except conference abstracts	Texts not published in scientific journals (e.g., book chapters) or conference abstracts
All publication years, all countries	N/A

MDA, mass drug administration; N/A, not applicable; NTD, neglected tropical disease; PC, preventive chemotherapy; PH, public health.